Los Angeles, CA – December 4, 2025 -Dr. Vadim Jucaud’s lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates age-dependent immune responses, offering a more accurate testing bed for evaluating cancer vaccine performance in older adults, the population most affected by cancer and often overlooked in traditional preclinical testing.
Los Angeles, CA – November 14, 2025 -The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce its collaboration with the California Institute of Technology (Caltech) on a newly awarded $2.8 million Discovery Stage Research (DISC0) grant from the California Institute for Regenerative Medicine (CIRM).
Los Angeles, CA – November 11, 2025 -The Terasaki Institute for Biomedical Innovation recently hosted a special Fireside Chat titled “Remembering Dr. Paul I. Terasaki”, honoring the extraordinary life and legacy of Dr. Paul I. Terasaki. The discussion brought together distinguished leaders who spoke about Dr. Terasaki’s impactful work across academia, medicine, and entrepreneurship.
Los Angeles, CA – November 7, 2025 -The Terasaki Institute proudly announces that Johnson V. John, Ph.D., Assistant Professor at the Institute, has been appointed as a standing member of the Musculoskeletal Tissue Engineering (MTE) Study Section within the Center for Scientific Review at the National Institutes of Health (NIH). His four-year term is scheduled to begin in November 2025.
Los Angeles, CA – October 21, 2025 - The Terasaki Institute had the honor of hosting the Royal Belgian Economic Mission this past week, marking a significant step forward in fostering international collaboration between Belgium and California’s biomedical communities. The delegation’s visit to the Institute’s Woodland Hills facility was part of a larger program organized by the Belgian Foreign Trade Agency (BFTA) and Flanders Investment & Trade (FIT).
Los Angeles, CA – October 2, 2025 - The Terasaki Institute for Biomedical Innovation (TIBI) announces a leadership transition as Dr. Ali Khademhosseini concluded his tenure as Chief Executive Officer and Executive Director. He is pursuing entrepreneurial ventures at the intersection of artificial intelligence and biomedical innovation. We wish Dr. Khademhosseini well in his future endeavors.
Los Angeles, CA – September 23, 2025 - A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University of Texas San Antonio, has developed a new microfluidic-based biosensing platform that allows monitoring cellular secretion of monoclonal antibody in real time. This approach can make monoclonal antibody production more efficient, ultimately lowering manufacturing costs so these important biotherapeutics become more accessible to patients.
Los Angeles, CA – September 5, 2025 - Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens. Using AlphaFold 3 (AF3), a AI/ML model, designed for protein structure prediction, the team demonstrated a novel approach to model T cell receptor–peptide/major histocompatibility complex (TCR-pMHC) interactions with growing accuracy.